T
Thomas Kelley
Researcher at University of Manchester
Publications - 4
Citations - 315
Thomas Kelley is an academic researcher from University of Manchester. The author has contributed to research in topics: Frontotemporal lobar degeneration & Progressive supranuclear palsy. The author has an hindex of 2, co-authored 4 publications receiving 302 citations.
Papers
More filters
Journal ArticleDOI
Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43.
Yvonne S Davidson,Thomas Kelley,Ian R. A. Mackenzie,Stuart Pickering-Brown,Daniel du Plessis,David Neary,Julie S. Snowden,David M. A. Mann +7 more
TL;DR: It is concluded that the UBQ-ir lesions of FTLD and MND are defined by the presence of TDP-43, and that these disorders can be subsumed into a single disease entity under the umbrella of T DP-43 proteinopathy.
Journal ArticleDOI
TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing
Yvonne S Davidson,Hanan Amin,Thomas Kelley,Jing Shi,Jing Shi,Jinzhou Tian,Jinzhou Tian,Ravindran Kumaran,Tammaryn Lashley,Andrew J. Lees,Daniel DuPlessis,David Neary,Julie S. Snowden,Haruhiko Akiyama,Tetsuaki Arai,Masato Hasegawa,Rina Bandopadhyay,Steve Sikkink,Stuart Pickering-Brown,David M. A. Mann +19 more
TL;DR: TDP-43 negative, UBQ-ir inclusions appear to be more related to ageing than neurodegeneration, and are without apparent diagnostic significance, but present studies indicate that this is not tau, neurofilament or internexin proteins.
Journal ArticleDOI
Foundation programme 2009
Thomas Kelley,Emily Finnigan +1 more
TL;DR: Thomas Kelley and Emily Finnigan as discussed by the authors explain how recruitment will work for UK junior doctors starting next August, starting from next year, and how they will be recruited and trained in the UK.
Journal ArticleDOI
Abdominal aortic aneurysms
TL;DR: Thomas Kelley and colleagues discuss the surgical options for treating central giant cell granuloma and the current treatment options are limited.